Onternabez

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Onternabez (also known as HU-308, HU308, PPP-003, and ARDS-003) is a synthetic cannabinoid that acts as a potent cannabinoid agonist. It is highly selective for the cannabinoid-2 receptor (CB 2 receptor) subtype, with a selectivity more than 5,000 times greater for the CB 2 receptor than the CB 1 receptor. The synthesis and characterization of onternabez took place in the laboratory of Raphael Mechoulam at the Hebrew University of Jerusalem (the HU in HU-308) in the late 1990s. The pinene dimethoxy-DMH-CBD derivative onternabez was identified as a potent peripheral CB 2 -selective agonist in in vitro and animal studies in 1990 and 1999.

Onternabez (also known as HU-308, HU308, PPP-003, and ARDS-003) is a synthetic cannabinoid that acts as a potent cannabinoid agonist. It is highly selective for the cannabinoid-2 receptor (CB 2 receptor) subtype, with a selectivity more than 5,000 times greater for the CB 2 receptor than the CB 1 receptor. The synthesis and characterization of onternabez took place in the laboratory of Raphael Mechoulam at the Hebrew University of Jerusalem (the HU in HU-308) in the late 1990s. The pinene dimethoxy-DMH-CBD derivative onternabez was identified as a potent peripheral CB 2 -selective agonist in in vitro and animal studies in 1990 and 1999.

Legal status

Onternabez is non-psychoactive and not scheduled at the federal level in the United States. It is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess there.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1305248176 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.